Novartis Inks Second Off-Label Settlement With DoJ, Paying $72.5 Million Over TOBI Marketing
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis still faces government investigations over its marketing of five other drugs; FDA issues a warning letter over its promotion of Gleevec on two company-sponsored websites.